Molecular Factor |
Chromosomal Location |
Alternative Names/Terms |
Chapters |
β-actin |
|
|
Expression Profiling, Oncotype DX Assay |
10p12, loss of |
10p12 |
|
Phyllodes Tumor |
10q, loss of |
10q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
11q, gain of |
11q |
|
DNA Analysis |
11q, loss of |
11q |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
13, loss of |
13 |
|
Phyllodes Tumor |
13q, gain of |
13q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
13q, loss of |
13q |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Myofibroblastoma |
13q, rearrangements of |
13q |
|
Lipoma and Angiolipoma |
13q14, loss of |
13q14 |
|
Myofibroblastoma |
14q, loss of |
14q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
15q, gain of |
15q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
16p, gain of |
16p |
|
DNA Analysis; Invasive Lobular Carcinoma |
16p, loss of |
16p |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
16q, loss of |
16q |
|
Atypical Ductal Hyperplasia; Columnar Cell Change with or without Flat Atypia; DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Invasive Lobular Carcinoma; Lobular Carcinoma In Situ; Myofibroblastoma; Risk Factors for Developing Breast Carcinoma; Tubular/Cribriform Carcinoma |
16q, rearrangements of |
16q |
|
Lipoma and Angiolipoma |
17p, loss of |
17p |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
17p13.1 |
17p13.1 |
|
Invasive Micropapillary Carcinoma |
17q, gain of |
17q |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
17q12 |
17q12 |
|
HER2; HER2 Positive Carcinoma |
19p, loss of |
19p |
|
DNA Analysis |
19q, gain of |
19q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; DNA Analysis |
19q, loss of |
19q |
|
DNA Analysis |
1p, gain of |
1p |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Lobular Carcinoma In Situ |
1p, loss of |
1p |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
1q, gain of |
1q |
|
Atypical Ductal Hyperplasia; DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Fibroadenoma; Invasive Lobular Carcinoma; Lobular Carcinoma In Situ; Phyllodes Tumor; Secretory Carcinoma; Tubular/Cribriform Carcinoma |
1q, loss of |
1q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
20q, gain of |
20q |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
22q, loss of |
22q |
|
DNA Analysis; Secretory Carcinoma |
2p16 |
2p16 |
|
Fibroadenoma |
2q, gain of |
2q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
3p24, loss of |
3p24 |
|
Phyllodes Tumor |
5q, loss of |
5q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
6q, gain of |
6q |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
7p12, loss of |
7p12 |
|
Phyllodes Tumor |
8p, loss of |
8p |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Invasive Micropapillary Carcinoma |
8q, gain of |
8q |
|
DNA Analysis; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Invasive Micropapillary Carcinoma; Secretory Carcinoma |
9p21 |
9p21 |
p16INK4a;Cyclin dependent kinase 2a (CDKN2A/B) |
Phyllodes Tumor |
adenomatosis polyposis coli |
|
APC |
Implant Pathology |
APC |
|
adenomatosis polyposis coli |
Fibromatosis |
ASPL |
17q25.3 |
Alveolar soft part sarcoma chromosome region, candidate 1 (ASPSCR1) |
Granular Cell Tumor |
ASPL-TFE3 |
t(X;17)(p11.2;q25) |
|
Granular Cell Tumor |
ATM |
11q22-23 |
ataxia telangiectasia mutated |
Hereditary Cancer |
BAG1 |
9p12 |
BCL2-associated athanogene |
Expression Profiling, Oncotype DX Assay |
Basal-like |
|
|
Basal-like Carcinomas; Expression Profiling, mRNA; Expression Profiling, Protein; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Locally Recurrent Carcinoma |
Basal-like/triple negative |
|
|
Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type) |
BCL2 |
18q21.3 |
B-cell CLL/lymphoma 2 |
Expression Profiling, Oncotype DX Assay |
Beta-catenin |
3p21 |
CTNNB1 |
Granular Cell Tumor; Nodular Fasciitis; Tubulolobular Carcinoma |
BRCA1 |
17q21 |
breast cancer 1, early onset |
Basal-like Carcinomas; Diabetic Mastopathy/Lymphocytic Mastopathy; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Expression Profiling, mRNA; HER2 Positive Carcinoma; Hereditary Cancer; Hormone Receptors (ER/PR); Lobular Carcinoma In Situ; Lymphoma; Mastectomies; Medullary Carcinoma; Risk Factors for Developing Breast Carcinoma |
BRCA2 |
13q12.3 |
breast cancer 2, early onset |
Gynecomastia; HER2 Positive Carcinoma; Hereditary Cancer; Hormone Receptors (ER/PR); Lobular Carcinoma In Situ; Mastectomies; Medullary Carcinoma; Risk Factors for Developing Breast Carcinoma |
BRIP1 |
17q22.2 |
BRCA1 interacting protein C-terminal helicase 1 |
Hereditary Cancer |
CD68 |
17p13 |
|
Expression Profiling, Oncotype DX Assay; Fat Necrosis; Granular Cell Tumor; Nodular Fasciitis |
CDC2 |
|
|
Expression Profiling, mRNA |
CDC20 |
|
|
Expression Profiling, mRNA; Histologic Grade |
CDH1 |
16q22.1 |
E-cadherin |
Hereditary Cancer; Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Lobular Carcinoma In Situ |
CDH11 |
16q22.1 |
cadherin 11, type 2, OB-cadherin (osteoblast) |
Lobular Carcinoma In Situ |
CDX-2 |
13q12.3 |
caudal related homologue 2 |
Invasive Lobular Carcinoma; Metastases to the Breast |
CHEK2 |
22q12.1 |
CHK2 checkpoint homolog (S. pombe) |
Gynecomastia; Hereditary Cancer; Risk Factors for Developing Breast Carcinoma |
CK19 |
17q21.2 |
|
Circulating Tumor Cells |
c-myc |
8q24.21 |
v-myc myelocytomatosis viral oncogene homolog (avian) |
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
CTSL2 |
9q22.2 |
cathepsin L2 |
Expression Profiling, Oncotype DX Assay |
der(17)t(X;17)(p11;q25) |
|
|
Granular Cell Tumor |
E-cadherin |
16q22.1 |
CDH1 |
Anatomic Structure and Lifecycle Changes; Atypical Ductal Hyperplasia; Atypical Lobular Hyperplasia; Collagenous Spherulosis; Ductal Carcinoma In Situ; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Epithelial Hyperplasia; HER2 Positive Carcinoma; Hereditary Cancer; Invasive Apocrine Carcinoma; Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Micropapillary Carcinoma; Lobular Carcinoma In Situ; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Sclerosing Adenosis; Secretory Carcinoma; Tubulolobular Carcinoma |
EGFR |
7p12 |
Epidermal growth factor receptor; ERBB1; HER1 |
Basal-like Carcinomas; Expression Profiling, mRNA; Expression Profiling, Protein; HER2; Hereditary Cancer; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Locally Recurrent Carcinoma; Low-Grade Adenosquamous Carcinoma; Metaplastic Carcinoma; Mucinous (Colloid) Carcinoma; Secretory Carcinoma |
ER |
6q25.1 |
estrogen receptor |
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Atypical Ductal Hyperplasia; Atypical Lobular Hyperplasia; Basal-like Carcinomas; Carcinomas with Extensive Intraductal Component; Checklist for the Reporting of Invasive Breast Carcinoma; Core Needle Biopsies; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ with Microinvasion; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; Fibromatosis; General Considerations; Gynecomastia; Hamartoma (Fibroadenolipoma); HER2; HER2 Positive Carcinoma; Histologic Grade; Hormone Receptors (ER/PR); Inflammatory Carcinoma; Introduction: Prognostic and Predictive Factors; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Micropapillary Carcinoma; Invasive Papillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Lymph Node Metastases; Lymphoma; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Myofibroblastoma Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Sclerosing Adenosis; Secretory Carcinoma; Size and Multiple Foci; Syringomatous Adenoma of the Nipple; Tubular/Cribriform Carcinoma; Tubulolobular Carcinoma |
ESR2 |
14q23.2 |
estrogen receptor 2 (ER beta) |
Hormone Receptors (ER/PR) |
Estrogen receptor |
6q25.1 |
ER |
Anatomic Structure and Lifecycle Changes; Basal-like Carcinomas; Carcinomas with Extensive Intraductal Component; Checklist for the Reporting of Invasive Breast Carcinoma; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ, Paget Disease; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; Fibroadenoma; Granular Cell Tumor; Gynecomastia; HER2 Positive Carcinoma; Hereditary Cancer; Hormone Receptors (ER/PR); Iatrogenic Changes; Invasive Apocrine Carcinoma; Invasive Micropapillary Carcinoma; Invasive Papillary Carcinoma; Locally Recurrent Carcinoma; Lymphoma; Microglandular Adenosis; Neoadjuvant Therapy; Risk Factors for Developing Breast Carcinoma; Sclerosing Adenosis |
ETV6 |
12p13 |
ets variant 6 |
Secretory Carcinoma |
ETV6-NTRK3 |
t(12;15)(p13;q25) |
|
Secretory Carcinoma |
GAPDH |
12p13 |
glyceraldehyde-3-phosphate dehydrogenase |
Expression Profiling, Oncotype DX Assay |
GRB7 |
17q12 |
growth factor receptor-bound protein 7 |
Expression Profiling, mRNA |
GSTM1 |
1p13.3 |
glutathione S-transferase mu 1 |
Expression Profiling, Oncotype DX Assay |
GUS |
|
|
Expression Profiling, Oncotype DX Assay |
HER2 |
17q12 |
c-erbB-2 |
Basal-like Carcinomas; Carcinomas with Extensive Intraductal Component; Checklist for the Reporting of Invasive Breast Carcinoma; Circulating Tumor Cells; Core Needle Biopsies; DNA Analysis; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ, Paget Disease; Encapsulated Papillary Carcinoma; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; General Considerations; Hamartoma (Fibroadenolipoma) HER2; HER2 Positive Carcinoma; Hereditary Cancer; Histologic Grade; Hormone Receptors (ER/PR); Inflammatory Carcinoma; Introduction: Prognostic and Predictive Factors; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Micropapillary Carcinoma; Invasive Papillary Carcinoma; Lobular Carcinoma In Situ Locally Recurrent Carcinoma; Low-Grade Adenosquamous Carcinoma; Lymph Node Metastases; Margins and Reexcisions Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Nipple Adenoma; Nonproliferative Changes; Secretory Carcinoma; Size and Multiple Foci; Tubular/Cribriform Carcinoma; Tubulolobular Carcinoma |
HER2-type |
|
|
Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type) |
HOXB13 |
17q21.2 |
homeobox B13 |
Expression Profiling, mRNA |
IL17BR |
|
|
Expression Profiling, mRNA |
Ki-67 |
10q26.2 |
|
Anatomic Structure and Lifecycle Changes; Basal-like Carcinomas; Ductal Carcinoma In Situ, Paget Disease; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; Fibroadenoma; Hemangiomas; HER2 Positive Carcinoma; Hereditary Cancer; Histologic Grade; Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Lymph-Vascular Invasion; Phyllodes Tumor; Sclerosing Adenosis; Tubular/Cribriform Carcinoma |
KIT |
4q11-q12 |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; c-Kit; CD117 |
Adenoid Cystic Carcinoma |
KPNA2 |
17q24.2 |
karyopherin alpha 2 (RAG cohort 1, importin alpha 1) |
Expression Profiling, mRNA; Histologic Grade |
Luminal A |
|
|
Basal-like Carcinomas; Ductal Carcinoma In Situ; Expression Profiling, mRNA; Expression Profiling, Protein; Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Locally Recurrent Carcinoma; Margins and Reexcisions |
Luminal B |
|
|
Ductal Carcinoma In Situ; Expression Profiling, mRNA; Expression Profiling, Protein; Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Margins and Reexcisions |
Luminal type A |
|
|
Mucinous (Colloid) Carcinoma |
MLL |
11q23 |
HRX;ALL1 |
Mucocele-like Lesions |
MMP11 |
22q11.2 |
matrix metallopeptidase 11 (stromelysin 3) |
Expression Profiling, Oncotype DX Assay |
MUC2 |
11p15.5 |
mucin 2, oligomeric mucus/gel-forming |
Mucinous (Colloid) Carcinoma |
MUC6 |
11p15.5 |
mucin 6, oligomeric mucus/gel-forming |
Mucinous (Colloid) Carcinoma; Mucocele-like Lesions |
MYB |
6q22-q23 |
v-myb myeloblastosis viral oncogene homolog (avian) |
Adenoid Cystic Carcinoma |
MYBL2 |
20q13.1 |
v-myb myeloblastosis viral oncogene homolog (avian)-like 2 |
Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay |
MYC |
c-myc |
|
Invasive Micropapillary Carcinoma |
MZL |
|
|
Lymphoma |
NFIB |
9p24.1 |
nuclear factor I/B |
Adenoid Cystic Carcinoma |
P53 |
17p13.1 |
TP53 |
Basal-like Carcinomas; HER2 Positive Carcinoma; Hereditary Cancer; Metaplastic Carcinoma; Risk Factors for Developing Breast Carcinoma; Secretory Carcinoma |
PAX3 |
2q35 |
Paired-box (PAX) gene 3 |
Phyllodes Tumor |
PR |
11q22-q23 |
progesterone receptor |
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Basal-like Carcinomas; Checklist for the Reporting of Invasive Breast Carcinoma; Core Needle Biopsies; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ with Microinvasion; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; General Considerations; Gynecomastia; Hamartoma (Fibroadenolipoma); HER2; HER2 Positive Carcinoma; Histologic Grade; Hormone Receptors (ER/PR); Inflammatory Carcinoma; Introduction: Prognostic and Predictive Factors; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Micropapillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Lymph Node Metastases; Lymphoma; Margins and Reexcisions; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Myofibroblastoma; Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Secretory Carcinoma; Size and Multiple Foci; Syringomatous Adenoma of the Nipple; Tubular/Cribriform Carcinoma; Tubulolobular Carcinoma |
PRKAR1A |
17q23-q24 |
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) |
Fibroadenoma |
Progesterone receptor |
11q22-q23 |
PR |
Anatomic Structure and Lifecycle Changes; Atypical Lobular Hyperplasia; Checklist for the Reporting of Invasive Breast Carcinoma; Ductal Carcinoma In Situ, Paget Disease; Encapsulated Papillary Carcinoma; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Fibroadenoma; Fibromatosis; Granular Cell Tumor; Gynecomastia; Hormone Receptors (ER/PR); Introduction: Prognostic and Predictive Factors; Invasive Apocrine Carcinoma; Invasive Micropapillary Carcinoma; Invasive Papillary Carcinoma; Lobular Carcinoma In Situ; Low-Grade Adenosquamous Carcinoma; Microglandular Adenosis; Myofibroblastoma; Neuroendocrine/Small Cell Carcinoma; Pseudoangiomatous Stromal Hyperplasia; Risk Factors for Developing Breast Carcinoma; Syringomatous Adenoma of the Nipple; Tubulolobular Carcinoma |
PTEN |
10q23.3 |
phosphatase and tensin homolog |
Hamartoma (Fibroadenolipoma); Hereditary Cancer; Invasive Apocrine Carcinoma; Risk Factors for Developing Breast Carcinoma |
RPLPO |
|
|
Expression Profiling, Oncotype DX Assay |
SCUBE2 |
11p15.3 |
signal peptide, CUB domain, EGF-like 2 |
Expression Profiling, Oncotype DX Assay |
SIX1 |
14q23.1 |
SIX homeobox 1 |
Phyllodes Tumor |
STK11/LKB1 |
19p13.3 |
serine/threonine kinase 11 |
Hereditary Cancer |
STK15 |
20q13 |
aurora kinase A (AURKA) |
Expression Profiling, Oncotype DX Assay |
TFE3 |
Xp11.2 |
transcription factor E3 |
Granular Cell Tumor |
TFRC |
3q29 |
transferrin receptor; CD71; p90 |
Expression Profiling, Oncotype DX Assay |
TOP2A |
17q21-q22 |
topoisomerase (DNA) II alpha 170kDa |
HER2 Positive Carcinoma |
TP53 |
17p13.1 |
P53 |
Basal-like Carcinomas; Hereditary Cancer; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Medullary Carcinoma |
Triple negative |
|
|
Basal-like Carcinomas; Carcinomas with Extensive Intraductal Component; Ductal Carcinoma In Situ; Expression Profiling, mRNA; Expression Profiling, Protein; HER2 Positive Carcinoma; Introduction: Prognostic and Predictive Factors; Margins and Reexcisions; Basal-like Carcinomas |
VEGF |
6p12 |
vascular endothelial growth factor A (VEGFA) |
Basal-like Carcinomas; Inflammatory Carcinoma |
WISP3 |
6q21 |
WNT1 inducible signaling pathway protein 3 |
Inflammatory Carcinoma |
WT1 |
11p13 |
Wilms tumor 1 |
Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Micropapillary Carcinoma; Lymph Node Metastases; Metastases to the Breast |
X, loss of |
X |
|
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma |
